Soluble CD163 and mannose receptor as markers of liver disease severity and prognosis in patients with primary biliary cholangitis

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

Standard

Soluble CD163 and mannose receptor as markers of liver disease severity and prognosis in patients with primary biliary cholangitis. / Bossen, Lars; Rebora, Paola; Bernuzzi, Francesca; Jepsen, Peter; Gerussi, Alessio; Andreone, Pietro; Galli, Andrea; Terziroli, Benedetta; Alvaro, Domenico; Labbadia, Giancarlo; Aloise, Chiara; Baiocchi, Leonardo; Giannini, Edoardo; Abenavoli, Ludovico; Toniutto, Pierluigi; Marra, Fabio; Marzioni, Marco; Niro, Grazia; Floreani, Annarosa; Møller, Holger J.; Valsecchi, Maria G.; Carbone, Marco; Grønbæk, Henning; Invernizzi, Pietro.

I: Liver International, Bind 40, Nr. 6, 06.2020, s. 1408-1414.

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

Harvard

Bossen, L, Rebora, P, Bernuzzi, F, Jepsen, P, Gerussi, A, Andreone, P, Galli, A, Terziroli, B, Alvaro, D, Labbadia, G, Aloise, C, Baiocchi, L, Giannini, E, Abenavoli, L, Toniutto, P, Marra, F, Marzioni, M, Niro, G, Floreani, A, Møller, HJ, Valsecchi, MG, Carbone, M, Grønbæk, H & Invernizzi, P 2020, 'Soluble CD163 and mannose receptor as markers of liver disease severity and prognosis in patients with primary biliary cholangitis', Liver International, bind 40, nr. 6, s. 1408-1414. https://doi.org/10.1111/liv.14466

APA

Bossen, L., Rebora, P., Bernuzzi, F., Jepsen, P., Gerussi, A., Andreone, P., Galli, A., Terziroli, B., Alvaro, D., Labbadia, G., Aloise, C., Baiocchi, L., Giannini, E., Abenavoli, L., Toniutto, P., Marra, F., Marzioni, M., Niro, G., Floreani, A., ... Invernizzi, P. (2020). Soluble CD163 and mannose receptor as markers of liver disease severity and prognosis in patients with primary biliary cholangitis. Liver International, 40(6), 1408-1414. https://doi.org/10.1111/liv.14466

CBE

Bossen L, Rebora P, Bernuzzi F, Jepsen P, Gerussi A, Andreone P, Galli A, Terziroli B, Alvaro D, Labbadia G, Aloise C, Baiocchi L, Giannini E, Abenavoli L, Toniutto P, Marra F, Marzioni M, Niro G, Floreani A, Møller HJ, Valsecchi MG, Carbone M, Grønbæk H, Invernizzi P. 2020. Soluble CD163 and mannose receptor as markers of liver disease severity and prognosis in patients with primary biliary cholangitis. Liver International. 40(6):1408-1414. https://doi.org/10.1111/liv.14466

MLA

Vancouver

Author

Bossen, Lars ; Rebora, Paola ; Bernuzzi, Francesca ; Jepsen, Peter ; Gerussi, Alessio ; Andreone, Pietro ; Galli, Andrea ; Terziroli, Benedetta ; Alvaro, Domenico ; Labbadia, Giancarlo ; Aloise, Chiara ; Baiocchi, Leonardo ; Giannini, Edoardo ; Abenavoli, Ludovico ; Toniutto, Pierluigi ; Marra, Fabio ; Marzioni, Marco ; Niro, Grazia ; Floreani, Annarosa ; Møller, Holger J. ; Valsecchi, Maria G. ; Carbone, Marco ; Grønbæk, Henning ; Invernizzi, Pietro. / Soluble CD163 and mannose receptor as markers of liver disease severity and prognosis in patients with primary biliary cholangitis. I: Liver International. 2020 ; Bind 40, Nr. 6. s. 1408-1414.

Bibtex

@article{cbebdb3264854171b75d3c52397a5bd3,
title = "Soluble CD163 and mannose receptor as markers of liver disease severity and prognosis in patients with primary biliary cholangitis",
abstract = "Introduction: In primary biliary cholangitis (PBC), macrophages are involved in liver inflammation and fibrosis. The macrophage activation markers, soluble (s)CD163 and mannose receptor (sMR) are associated with liver disease severity and prognosis in other chronic liver diseases. We aimed to investigate sCD163 and sMR in patients with PBC. Methods: We investigated PBC patients from the Italian PBC Study Group cohort and measured macrophage activation markers in serum at study enrolment. Patients were followed from enrolment until they experienced an event or were censored at their last visit. Events were defined as follows: (a) death from a liver-related cause; or (b) liver transplantation (LT) for PBC. We used Cox regression to investigate the association between sCD163 and sMR and long-term prognosis. Results: In total, 202 PBC patients were included. Median age was 62 years (interquartile range (IQR), 53-71) at enrolment and 93% were women. Median sCD163 was 3.43 mg/L (IQR 2.48-5.35) and median sMR was 0.35 mg/L (IQR 0.28-0.45). There was an increase in sCD163 and sMR with increasing alkaline phosphatase. Two hundred and one patients were followed for a median of 8.6 years, and sCD163 and sMR predicted long-term risk of liver-related death or LT in univariate analyses, while sCD163 was also associated with outcome after confounder adjusting (adjusted HR = 1.14, 95% CI 1.00-1.30). Finally, we showed an increase in the prediction accuracy of poor outcome by adding sCD163 to the UK-PBC risk score. Conclusion: The macrophage activation markers sCD163 and sMR represent a non-invasive measure of PBC disease severity that provides useful long-term prognostic information.",
keywords = "macrophage activation markers, non-invasive markers, primary biliary cholangitis, prognostic markers",
author = "Lars Bossen and Paola Rebora and Francesca Bernuzzi and Peter Jepsen and Alessio Gerussi and Pietro Andreone and Andrea Galli and Benedetta Terziroli and Domenico Alvaro and Giancarlo Labbadia and Chiara Aloise and Leonardo Baiocchi and Edoardo Giannini and Ludovico Abenavoli and Pierluigi Toniutto and Fabio Marra and Marco Marzioni and Grazia Niro and Annarosa Floreani and M{\o}ller, {Holger J.} and Valsecchi, {Maria G.} and Marco Carbone and Henning Gr{\o}nb{\ae}k and Pietro Invernizzi",
year = "2020",
month = jun,
doi = "10.1111/liv.14466",
language = "English",
volume = "40",
pages = "1408--1414",
journal = "Liver International",
issn = "1478-3223",
publisher = "Wiley-Blackwell Publishing Ltd.",
number = "6",

}

RIS

TY - JOUR

T1 - Soluble CD163 and mannose receptor as markers of liver disease severity and prognosis in patients with primary biliary cholangitis

AU - Bossen, Lars

AU - Rebora, Paola

AU - Bernuzzi, Francesca

AU - Jepsen, Peter

AU - Gerussi, Alessio

AU - Andreone, Pietro

AU - Galli, Andrea

AU - Terziroli, Benedetta

AU - Alvaro, Domenico

AU - Labbadia, Giancarlo

AU - Aloise, Chiara

AU - Baiocchi, Leonardo

AU - Giannini, Edoardo

AU - Abenavoli, Ludovico

AU - Toniutto, Pierluigi

AU - Marra, Fabio

AU - Marzioni, Marco

AU - Niro, Grazia

AU - Floreani, Annarosa

AU - Møller, Holger J.

AU - Valsecchi, Maria G.

AU - Carbone, Marco

AU - Grønbæk, Henning

AU - Invernizzi, Pietro

PY - 2020/6

Y1 - 2020/6

N2 - Introduction: In primary biliary cholangitis (PBC), macrophages are involved in liver inflammation and fibrosis. The macrophage activation markers, soluble (s)CD163 and mannose receptor (sMR) are associated with liver disease severity and prognosis in other chronic liver diseases. We aimed to investigate sCD163 and sMR in patients with PBC. Methods: We investigated PBC patients from the Italian PBC Study Group cohort and measured macrophage activation markers in serum at study enrolment. Patients were followed from enrolment until they experienced an event or were censored at their last visit. Events were defined as follows: (a) death from a liver-related cause; or (b) liver transplantation (LT) for PBC. We used Cox regression to investigate the association between sCD163 and sMR and long-term prognosis. Results: In total, 202 PBC patients were included. Median age was 62 years (interquartile range (IQR), 53-71) at enrolment and 93% were women. Median sCD163 was 3.43 mg/L (IQR 2.48-5.35) and median sMR was 0.35 mg/L (IQR 0.28-0.45). There was an increase in sCD163 and sMR with increasing alkaline phosphatase. Two hundred and one patients were followed for a median of 8.6 years, and sCD163 and sMR predicted long-term risk of liver-related death or LT in univariate analyses, while sCD163 was also associated with outcome after confounder adjusting (adjusted HR = 1.14, 95% CI 1.00-1.30). Finally, we showed an increase in the prediction accuracy of poor outcome by adding sCD163 to the UK-PBC risk score. Conclusion: The macrophage activation markers sCD163 and sMR represent a non-invasive measure of PBC disease severity that provides useful long-term prognostic information.

AB - Introduction: In primary biliary cholangitis (PBC), macrophages are involved in liver inflammation and fibrosis. The macrophage activation markers, soluble (s)CD163 and mannose receptor (sMR) are associated with liver disease severity and prognosis in other chronic liver diseases. We aimed to investigate sCD163 and sMR in patients with PBC. Methods: We investigated PBC patients from the Italian PBC Study Group cohort and measured macrophage activation markers in serum at study enrolment. Patients were followed from enrolment until they experienced an event or were censored at their last visit. Events were defined as follows: (a) death from a liver-related cause; or (b) liver transplantation (LT) for PBC. We used Cox regression to investigate the association between sCD163 and sMR and long-term prognosis. Results: In total, 202 PBC patients were included. Median age was 62 years (interquartile range (IQR), 53-71) at enrolment and 93% were women. Median sCD163 was 3.43 mg/L (IQR 2.48-5.35) and median sMR was 0.35 mg/L (IQR 0.28-0.45). There was an increase in sCD163 and sMR with increasing alkaline phosphatase. Two hundred and one patients were followed for a median of 8.6 years, and sCD163 and sMR predicted long-term risk of liver-related death or LT in univariate analyses, while sCD163 was also associated with outcome after confounder adjusting (adjusted HR = 1.14, 95% CI 1.00-1.30). Finally, we showed an increase in the prediction accuracy of poor outcome by adding sCD163 to the UK-PBC risk score. Conclusion: The macrophage activation markers sCD163 and sMR represent a non-invasive measure of PBC disease severity that provides useful long-term prognostic information.

KW - macrophage activation markers

KW - non-invasive markers

KW - primary biliary cholangitis

KW - prognostic markers

UR - http://www.scopus.com/inward/record.url?scp=85083798684&partnerID=8YFLogxK

U2 - 10.1111/liv.14466

DO - 10.1111/liv.14466

M3 - Journal article

C2 - 32279422

AN - SCOPUS:85083798684

VL - 40

SP - 1408

EP - 1414

JO - Liver International

JF - Liver International

SN - 1478-3223

IS - 6

ER -